Ultime notizie per Gossamer Bio (NASDAQ:GOSS) Azioni

GOSSAMER BIO INC

Gossamer Bio

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

Gossamer Bio Inc

GOSSAN RESOURCES LTD CDA by Gossan Resources Ltd.

Gossan Resources Ltd

<a href="https://www.sec.gov/Archives/edgar/data/1108426/000110842625000069/pnm-20250624.htm">https://www.sec.gov/Archives/edgar/data/1108426/000110842625000069/pnm-20250624.htm</a>

News

General

TXNM

TXNM Energy Enters Stock Purchase Agreement With Zimmer Partners; Purchasers To Buy 3,615,003 TXNM Shares At $55.325 Each

<a href="https://www.sec.gov/Archives/edgar/data/846475/000155837025008834/zyxi-20250618x8k.htm">https://www.sec.gov/Archives/edgar/data/846475/000155837025008834/zyxi-20250618x8k.htm</a>

ZYXI

Zynex Executes Workforce Reduction Affecting 86 Corporate Roles; Expects $5M In Annualized Cost Savings From Workforce Reduction; Awaits Response To Appeal On Tricare Payment Suspension

Unum Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNM#NYSE">UNM</a>) has outperformed the market over the past 5 years by 22.83% on an annualized basis producing an average annual return of 37.62%. Currently, Unum Gr has a market capitalization of $13.97 billion. 
Buying $100 In UNM: If an investor had bought $100 of UNM stock 5 years ago, it would be worth $511.79 today based on a price of $79.43 for UNM at the time of writing.
<h3>Unum Gr's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750800626_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much $100 Invested In Unum Gr 5 Years Ago Would Be Worth Today

BlackBerry Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) released its first-quarter results after Tuesday's closing bell. Here's a look at the details <a href="https://www.benzinga.com/pressreleases/25/06/ac46084333/blackberry-reports-first-quarter-fiscal-year-2026-results">in the report. </a>
The Details: BlackBerry reported quarterly earnings of two cents per share, which beat the analyst consensus estimate of zero cents. Quarterly revenue of $121.7 million beat the Street estimate of $112.18 million.
Read Next: <a href="https://www.benzinga.com/news/space/25/06/46055895/ast-spacemobile-stock-downgraded-rocket-lab-prepares-electron-launch-space-stock-countdown?utm_source=articleShare">AST SpaceMobile Stock Downgraded, Rocket Lab Prepares Electron Launch: Space Stock Countdown</a>
For the first quarter, BlackBerry reported: 
<ul class="wp-block-list">
<li>Total company non-GAAP gross margin was 75%.</li>
<li>QNX revenue delivered 8% year-over-year growth to $57.5 million; QNX adjusted gross margin was 81%. </li>
<li>Secure Communications revenue exceeded previously-provided guidance at $59.5 million; Secure Communications adjusted gross margin increased by 6 percentage points sequentially and 4 percentage points year-over-year to 70%. </li>
<li>Licensing revenue was $4.7 million, and adjusted EBITDA was $3.8 million. </li>
</ul>
&#8220;BlackBerry made a strong start to the new fiscal year, building on the solid foundation we as a company have laid over the past year,&#8221; said John J. Giamatteo, CEO of BlackBerry. 
&#8220;Both our QNX and Secure Communications divisions continue to execute effectively against their strategies, beating both top line and profitability expectations.&#8221;
Outlook: BlackBerry affirmed its fiscal 2026 adjusted EPS guidance of a range of eight cents to 10 cents. The company raised its fiscal 2026 revenue guidance from a range of $504 million to $534 million to a new range of between $508 million and $538 million, versus the $513.51 million estimate.
BB Price Action: According to data from<a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw"> Benzinga Pro</a>, BlackBerry stock was up 4.16% at $4.51 in Tuesday's extended trading. 
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/46056665/unitedhealth-cvs-among-major-insurers-to-fast-track-prior-authorizations-will-it-cut-profits-even-more?utm_source=articleShare">UnitedHealth, CVS Among Major Insurers To Fast-Track Prior Authorizations: Will It Cut Profits Even More?</a></li>
</ul>
Image: Shutterstock&nbsp;

Earnings

After-Hours Center

Movers

Tech

BlackBerry Stock Climbs After Better-Than-Expected Q1 Report: Details

Carver Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARV#NASDAQ">CARV</a>) reported quarterly losses of $(0.72) per share. This is a 3700 percent decrease over earnings of $0.02 per share from the same period last year. The company reported $5.507 million in sales this quarter. This is a 32.42 percent decrease over sales of $8.149 million the same period last year.

CARV

Carver Bancorp Q4 EPS $(0.72) Down From $0.02 YoY, Sales $5.507M Down From $8.149M YoY

QuantumScape Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>) shares are soaring in extended trading on Tuesday after the company announced that its Cobra separator process <a href="https://www.benzinga.com/pressreleases/25/06/b46083543/quantumscape-achieves-major-milestone-cobra-separator-process-enters-baseline-production">entered into baseline production</a>.
What Happened: Lithium-metal battery technology company QuantumScape said the start of baseline production for its Cobra separator marks a significant milestone in the scale-up of its production capabilities. 
Cobra is the foundation of QuantumScape&#8217;s high-throughput, continuous-flow separator production platform, which is designed to allow for faster production with a smaller footprint than previous ceramic separator manufacturing processes.
&#8220;Our team has made impressive strides in advancing Cobra, a technology that exemplifies our progress in scaling solid-state battery production,&#8221; said Siva Sivaram, CEO of QuantumScape. 
&#8220;By significantly improving throughput and shrinking the equipment footprint, Cobra gives us a powerful path forward for commercializing our next-generation battery technology.&#8221;
The company said the advancement in production is key to bringing its solid-state battery platform to market on a gigawatt scale. QuantumScape expects to continue to improve its production speed, efficiency and scalability with Cobra now in place as the new baseline.
<h1 class="wp-block-heading">How To Buy QS Stock</h1>
By now, you're likely curious about how to participate in the market for QuantumScape — be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option or sell a call option at a strike price above where shares are currently trading — either way, it allows you to profit off of the share price decline.
QS Price Action: <a href="http://benzinga.com/quote/QS">QuantumScape shares </a>were up 29.56% at $5.62 in after-hours trading Tuesday, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/06/46083408/intel-intc-shares-rise-as-chip-stocks-rebound-on-geopolitical-optimism">Intel (INTC) Shares Rise As Chip Stocks Rebound On Geopolitical Optimism</a></li>
</ul>
Photo: courtesy of QuantumScape.

QuantumScape Stock Is Surging After The Bell: What's Fueling The Move?

Envela Corporation Added As A Member Of The US Small-Cap Russell 2000 Index, Effective On June 30

Taylor Morrison Home (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMHC#NYSE">TMHC</a>) has outperformed the market over the past 5 years by 11.53% on an annualized basis producing an average annual return of 26.32%. Currently, Taylor Morrison Home has a market capitalization of $6.17 billion. 
Buying $1000 In TMHC: If an investor had bought $1000 of TMHC stock 5 years ago, it would be worth $3,422.37 today based on a price of $61.50 for TMHC at the time of writing.
<h3>Taylor Morrison Home's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750799716_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TMHC

If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today

Contracts

Jayud Global Logistics Secures $4.2M Government Subsidy From The Shenzhen Transportation Bureau For Charter Flight Operations

GBCI

GNTY

Guaranty Shareholders To Receive 1 Share Of Glacier Stock For Each Guaranty Share

Glacier Bancorp To Acquire Guaranty In An All-Stock Transaction; The Transaction Would Result In Aggregate Consideration Of $476.2M

BlackBerry (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BB#TSX">BB</a>) Q2 expected to be $0 to $0.01 vs $0.01 Est. sees Q2 sales of $115.000 million-$125.000 million vs $122.420 million analyst estimate.

Guidance

TSX:BB

BlackBerry Q2  expected to be $0 to $0.01 vs $0.01 Est; Sees Q2 Sales $115.000M-$125.000M vs $122.420M Est

BlackBerry (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BB#TSX">BB</a>) affirms FY2026 Adj EPS guidance from $0.08-$0.10 to $0.08-$0.10 vs $0.10 analyst estimate. Raises FY2026 sales outlook from $504.000 million-$534.000 million to $508.000 million-$538.000 million vs $513.050 million estimate.

BlackBerry Affirms FY2026 Adj EPS Guidance of $0.08-$0.10 vs $0.10 Est; Raises FY2026 Sales Guidance from $504.000M-$534.000M to $508.000M-$538.000M vs $513.050M Est

BlackBerry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) affirms FY2026 Adj EPS guidance from $0.08-$0.10 to $0.08-$0.10 vs $0.10 analyst estimate. Raises FY2026 sales outlook from $504.000 million-$534.000 million to $508.000 million-$538.000 million vs $513.510 million estimate.

BlackBerry Affirms FY2026 Adj EPS Guidance of $0.08-$0.10 vs $0.10 Est; Raises FY2026 Sales Guidance from $504.000M-$534.000M to $508.000M-$538.000M vs $513.510M Est

BlackBerry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) Q2 expected to be Breakeven - $0.01 vs $0.01 Est. sees Q2 sales of $115.000 million-$125.000 million vs $122.353 million analyst estimate.

BlackBerry Q2  expected to be $0 to $0.01 vs $0.01 Est; Sees Q2 Sales $115.000M-$125.000M vs $122.353M Est

Offerings

BBLG

Bone Biologics Corp For Mixed Shelf Of Up To $35M

BlackBerry (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BB#TSX">BB</a>) reported quarterly earnings of $0.02 per share. This is a 166.67 percent increase over losses of $(0.03) per share from the same period last year. The company reported quarterly sales of $121.700 million which beat the analyst consensus estimate of $112.180 million by 8.49 percent. This is a 15.49 percent decrease over sales of $144.000 million the same period last year.

Earnings Beats

BlackBerry Q1 Adj. EPS $0.02 Up From $(0.03) YoY, Sales $121.700M Beat $112.180M Estimate

BlackBerry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $0.00 by 566.67 percent. This is a 166.67 percent increase over losses of $(0.03) per share from the same period last year. The company reported quarterly sales of $121.700 million which beat the analyst consensus estimate of $112.185 million by 8.48 percent. This is a 15.49 percent decrease over sales of $144.000 million the same period last year.

BlackBerry Q1 Adj. EPS $0.02 Beats $0.00 Estimate, Sales $121.700M Beat $112.185M Estimate

<h3>Gainers</h3>
<ul>
<li>QuantumScape (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>) stock moved upwards by 29.8% to $5.62 during Tuesday's after-market session. The market value of their outstanding shares is at $2.3 billion. </li>
<li>Genius Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GNS#AMEX">GNS</a>) shares moved upwards by 8.72% to $0.76. The company's market cap stands at $38.1 million. </li>
<li>ZHONGCHAO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCMD#NASDAQ">ZCMD</a>) shares rose 6.19% to $1.2. The market value of their outstanding shares is at $31.5 million. </li>
<li>Foresight Autonomous (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRSX#NASDAQ">FRSX</a>) stock increased by 4.96% to $0.48. The company's market cap stands at $9.3 million. </li>
<li>Fly-E Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLYE#NASDAQ">FLYE</a>) shares increased by 4.46% to $1.17. The market value of their outstanding shares is at $51.1 million. </li>
<li>Jiuzi Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JZXN#NASDAQ">JZXN</a>) shares moved upwards by 4.31% to $0.94. The market value of their outstanding shares is at $9.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Torrid Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CURV#NYSE">CURV</a>) shares fell 25.5% to $3.8 during Tuesday's after-market session. The market value of their outstanding shares is at $533.5 million. </li>
<li>Boqii Holding (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BQ#AMEX">BQ</a>) shares fell 7.7% to $1.92. The market value of their outstanding shares is at $6.1 million. </li>
<li>Color Star Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADD#NASDAQ">ADD</a>) stock fell 7.66% to $0.95. </li>
<li>Wah Fu Education Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WAFU#NASDAQ">WAFU</a>) stock fell 5.56% to $1.36. The market value of their outstanding shares is at $6.1 million. </li>
<li>TH International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THCH#NASDAQ">THCH</a>) shares fell 4.7% to $2.64. The company's market cap stands at $88.3 million. The company's, Q1 earnings came out today. </li>
<li>Rent the Runway (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RENT#NASDAQ">RENT</a>) shares fell 4.39% to $4.8. The market value of their outstanding shares is at $18.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CURV

FLYE

FRSX

JZXN

RENT

THCH

WAFU

ZCMD

12 Consumer Discretionary Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Citius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTXR#NASDAQ">CTXR</a>) shares increased by 13.6% to $1.46 during Tuesday's after-market session. The company's market cap stands at $11.1 million. </li>
<li>Cibus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBUS#NASDAQ">CBUS</a>) stock rose 11.54% to $1.74. The company's market cap stands at $73.0 million. </li>
<li>LakeShore Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSB#NASDAQ">LSB</a>) shares rose 9.11% to $1.04. The company's market cap stands at $18.5 million. </li>
<li>NeuroOne Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMTC#NASDAQ">NMTC</a>) shares rose 6.62% to $0.74. The company's market cap stands at $32.9 million. </li>
<li>Ontrak (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTRK#NASDAQ">OTRK</a>) shares rose 6.62% to $1.12. The market value of their outstanding shares is at $5.6 million. </li>
<li>Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) stock increased by 6.29% to $26.0. The company's market cap stands at $118.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>XTL Biopharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTLB#NASDAQ">XTLB</a>) shares declined by 11.5% to $1.16 during Tuesday's after-market session. The market value of their outstanding shares is at $8.9 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) shares fell 10.35% to $0.61. The company's market cap stands at $10.3 million. </li>
<li>Forte Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBRX#NASDAQ">FBRX</a>) shares declined by 10.31% to $12.71. The market value of their outstanding shares is at $84.0 million. </li>
<li>InspireMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSPR#NASDAQ">NSPR</a>) stock declined by 8.55% to $2.25. The market value of their outstanding shares is at $77.2 million. </li>
<li>CASI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASI#NASDAQ">CASI</a>) shares declined by 8.09% to $1.25. The market value of their outstanding shares is at $19.0 million. </li>
<li>Lixte Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIXT#NASDAQ">LIXT</a>) shares decreased by 7.95% to $0.8. The market value of their outstanding shares is at $2.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CASI

CBUS

CTXR

FBRX

LIXT

NKTR

NMTC

NSPR

ONMD

OTRK

XTLB

12 Health Care Stocks Moving In Tuesday's After-Market Session

Press Releases

Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Gossamer Bio to Present Preclinical Data at the American Thoracic Society (ATS) 2025 International Conference

Gossamer Bio to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15, 2025

Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study

Presenting on Emerging Growth Conference 82 Day 1 on May 21; Register to live stream

Presenting on Emerging Growth Conference 82 Day 2 on May 22; Register to live stream

Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH

Comments

Gossamer Bio

Notizie

Ultime notizie per Gossamer Bio (NASDAQ:GOSS) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO